About Certara, Inc.
https://www.certara.comCertara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
CEO
William F. Feehery
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 162
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
UBS
Buy
Barclays
Overweight
Stephens & Co.
Overweight
Keybanc
Overweight
Morgan Stanley
Equal Weight
JMP Securities
Market Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
WASATCH ADVISORS LP
Shares:17.4M
Value:$162.15M
BLACKROCK, INC.
Shares:13.91M
Value:$129.62M
BLACKROCK INC.
Shares:13.42M
Value:$125.11M
Summary
Showing Top 3 of 272
About Certara, Inc.
https://www.certara.comCertara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $104.62M ▲ | $44.08M ▼ | $1.52M ▲ | 1.46% ▲ | $0.01 ▲ | $23.37M ▼ |
| Q2-2025 | $104.57M ▼ | $54.3M ▼ | $-1.97M ▼ | -1.88% ▼ | $-0.01 ▼ | $29.87M ▲ |
| Q1-2025 | $106M ▲ | $56.86M ▲ | $4.74M ▼ | 4.47% ▼ | $0.03 ▼ | $27.96M ▲ |
| Q4-2024 | $100.36M ▲ | $56.09M ▲ | $6.58M ▲ | 6.55% ▲ | $0.04 ▲ | $25.4M ▲ |
| Q3-2024 | $94.82M | $55.04M | $-1.37M | -1.45% | $-0.01 | $-6.41M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $172.71M ▲ | $1.54B ▼ | $471.05M ▼ | $1.06B ▼ |
| Q2-2025 | $162.27M ▼ | $1.54B ▼ | $472.87M ▼ | $1.07B ▼ |
| Q1-2025 | $179.09M ▼ | $1.56B ▼ | $476.73M ▼ | $1.08B ▲ |
| Q4-2024 | $179.18M ▼ | $1.58B ▲ | $516.45M ▲ | $1.06B ▲ |
| Q3-2024 | $233.02M | $1.54B | $489.82M | $1.05B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.52M ▲ | $32.31M ▲ | $-6.79M ▲ | $-14.48M ▲ | $10.45M ▲ | $32.09M ▲ |
| Q2-2025 | $-1.97M ▼ | $17.84M ▲ | $-6.96M ▼ | $-30.69M ▼ | $-16.82M ▼ | $17.91M ▲ |
| Q1-2025 | $4.74M ▼ | $17.35M ▼ | $-5.77M ▲ | $-14M ▼ | $-97K ▲ | $11.58M ▼ |
| Q4-2024 | $6.58M ▲ | $49.37M ▲ | $-97.16M ▼ | $-1.3M ▲ | $-53.84M ▼ | $43.53M ▲ |
| Q3-2024 | $-1.37M | $16.99M | $-5.51M | $-5.61M | $8.42M | $16.82M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $110.00M ▲ | $100.00M ▼ | $100.00M ▲ |
Revenue by Geography
| Region | Q3-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 Americas | $70.00M ▲ | $70.00M ▲ | $70.00M ▲ | $70.00M ▲ |
 Asia Pacific | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 EMEA | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $30.00M ▲ |
CEO
William F. Feehery
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 162
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
UBS
Buy
Barclays
Overweight
Stephens & Co.
Overweight
Keybanc
Overweight
Morgan Stanley
Equal Weight
JMP Securities
Market Perform
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
WASATCH ADVISORS LP
Shares:17.4M
Value:$162.15M
BLACKROCK, INC.
Shares:13.91M
Value:$129.62M
BLACKROCK INC.
Shares:13.42M
Value:$125.11M
Summary
Showing Top 3 of 272